Paratek Pharmaceuticals completes acquisition of Optinose
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2025
0mins
Acquisition Details: Paratek Pharmaceuticals has completed the acquisition of Optinose for approximately $330 million, which includes cash payments to shareholders and contingent value rights based on future sales milestones of Optinose's product XHANCE.
Impact of Acquisition: This merger enhances Paratek's portfolio by adding XHANCE to its existing antibiotic NUZYRA, while also leading to the delisting of Optinose's common stock from the Nasdaq Global Select Market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
